# Real Biological Digital Twin Pipeline

This roadmap defines the implementation boundary between the existing technical contracts and real biological validation. It is research/decision-support scope; it does not make clinical diagnoses or prescribe treatment.

## 1. Real microscopy analysis

```text
REAL MICROSCOPY
       ↓
SEGMENTATION
       ↓
CELL ID
       ↓
CELL TYPE
       ↓
CELL FEATURES
```

Required inputs: real microscopy/WSI data, metadata, calibration, expert annotations, QC and benchmark datasets.

## 2. Real Cell Health

```text
Cell features
     ↓
Biomarkers
     ↓
Health model
     ↓
Confidence
     ↓
Expert validation
```

Health labels must be biologically defined and validated before model claims are made.

## 3. Real Biological Age

```text
Cell type
     ↓
Aging biomarkers
     ↓
Age model
     ↓
Calibration
     ↓
Uncertainty
     ↓
Independent validation
```

Biological age is cell-type- and context-dependent; no universal single-cell age is assumed.

## 4. Real pathology

```text
Normal variation
       ↓
Alteration
       ↓
Pathological signal
       ↓
Localization
       ↓
Expert validation
```

The system must distinguish biological variation from pathological signals and retain evidence and uncertainty.

## 5. Temporal Twin

```text
T0 → T1 → T2 → T3 → ...
```

Longitudinal observations from the same subjects, structures, tissues and, where technically possible, cells are required to estimate change rates reliably.

## 6. Personal Baseline

```text
My normal
    ↓
Current state
    ↓
Deviation
    ↓
Trend
```

The baseline should be learned from the individual's history, with population comparison as a secondary reference.

## 7. Risk Map

```text
Cell
 ↓
Tissue
 ↓
Region
 ↓
Hand
 ↓
Risk
```

Risk aggregation should only become substantive after underlying biological models have independent validation. Every non-unknown signal requires evidence and confidence handling.

## 8. Simulation

```text
Current
 ├── no intervention
 ├── scenario A
 └── scenario B
          ↓
     Future state
```

Scenario results require validated transition models. Unvalidated scenarios must be explicitly marked as research simulations.

## 9. Predictive Digital Twin

```text
Current
 ↓
5 years
 ↓
10 years
 ↓
20 years
 ↓
50 years
```

Prediction intervals and uncertainty must be represented explicitly and should generally widen with prediction horizon unless validated otherwise.

## 10. Long-term Aging

```text
Cells
 ↓
Tissues
 ↓
Structures
 ↓
Person
```

Models should allow different aging rates at each biological level and update as longitudinal evidence accumulates.

## 11. Whole Body

```text
HAND
SKIN
MUSCLE
BONE
BLOOD
HEART
BRAIN
LIVER
KIDNEY
...
      ↓
HUMAN DIGITAL TWIN
```

Whole-body integration follows validated organ-level pipelines and a common identity, spatial and temporal contract.

## 12. Predictive medicine

```text
Detection
 ↓
Risk
 ↓
Simulation
 ↓
Prediction
 ↓
Diagnostic Support
 ↓
Monitoring
 ↓
Twin Update
```

This layer requires evidence, confidence, expert validation, auditability and safety controls. It is decision support, not autonomous diagnosis or treatment.

## Implementation principle

Build the first end-to-end path on real data before expanding the biological claims:

```text
REAL MICROSCOPY
      ↓
CELL SEGMENTATION
      ↓
CELL ID
      ↓
CELL TYPE
      ↓
CELL FEATURES
      ↓
CELL HEALTH
      ↓
SPATIAL 3D
```
